Solitary pancreas transplantation for nonuremic patients with labile insulin-dependent diabetes mellitus.

BACKGROUND Simultaneous pancreas-kidney transplantation has become a widely accepted treatment option for selected uremic patients with insulin-dependent diabetes mellitus (IDDM). Patient survival rates at 1 year exceed 90%, and rates of pancreas graft survival, 70%. However, solitary pancreas transplantation for nonuremic patients with IDDM has been controversial because of the less favorable outcome and the need for long-term immunosuppression with its associated morbidity and mortality. METHODS We studied the outcome of 225 solitary pancreas transplants during three immunosuppressive eras: the precyclosporine (CsA) era (n=83), the CsA era (n=118), and the tacrolimus era (n=24). Only patients with labile IDDM (e.g., hypoglycemic unawareness, insulin reactions, > or = 2 failed attempts at intensified insulin therapy for metabolic control) underwent solitary pancreas transplantation. Using univariate and multivariate analyses, we looked at patient and graft survival, the risk of surgical complications, and native kidney function during these three eras. RESULTS Pancreas graft survival improved significantly over time: 34% at 1 year after transplantation in the pre-CsA era, 52% in the CsA era, and 80% in the tacrolimus era (P=0.002). Pancreas graft loss due to rejection decreased from 50% at 1 year in the pre-CsA era, to 34% in the CsA era, to 9% in the tacrolimus era (P=0.008). The rate of technical failures (i.e., the risk of surgical complications) decreased from 30% in the pre-CsA era, to 14% in the CsA era, to 0% in the tacrolimus era (P=0.001). Patient survival rates at 1 year have ranged between 88% and 95% in the three eras (P=NS). Matching for at least one antigen on each HLA locus and avoiding HLA-B mismatches significantly decreased the incidence of rejection. The incidence of native kidney failure due to drug-induced toxicity decreased significantly over time, in part because only recipients with pretransplant creatinine clearance > or = 80 ml/min received transplants. CONCLUSIONS Solitary pancreas transplantation has become a viable alternative for nonuremic patients with labile IDDM. The risks of surgical complications and drug-induced nephrotoxicity have significantly decreased over time. Using tacrolimus as the mainstay immunosuppressant, patient and graft survival rates now no longer trail those of simultaneous pancreas-kidney transplantation.

[1]  D. Dunn,et al.  The surgical risk of pancreas transplantation in the cyclosporine era: an overview. , 1997, Journal of the American College of Surgeons.

[2]  P. Kuo,et al.  Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy. , 1996, Annals of surgery.

[3]  D. Dunn,et al.  Vascular graft thrombosis after pancreatic transplantation: univariate and multivariate operative and nonoperative risk factor analysis. , 1996, Journal of the American College of Surgeons.

[4]  R. Stratta,et al.  A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. , 1996, Transplantation.

[5]  D. Dunn,et al.  RECIPIENT RISK FACTORS HAVE AN IMPACT ON TECHNICAL FAILURE AND PATIENT AND GRAFT SURVIVAL RATES IN BLADDER‐DRAINED PANCREAS TRANSPLANTS , 1994, Transplantation.

[6]  R. Bilous,et al.  Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys , 1993, The Lancet.

[7]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[8]  J. Nerup Is there a need for pancreas transplantation? Con. , 1993, Transplantation proceedings.

[9]  R. Østerby,et al.  Blood Pressure Elevation Versus Abnormal Albuminuria in the Genesis and Prediction of Renal Disease in Diabetes , 1992, Diabetes Care.

[10]  G. Gill,et al.  Brittle Diabetes: A Report of the First International Conference on Brittle Diabetes , 1992, Diabetic Medicine.

[11]  C. Gross,et al.  Health-related quality of life outcomes of pancreas transplant recipients. , 1992, Clinical transplantation.

[12]  P. Morel,et al.  Long-term glucose control in patients with pancreatic transplants. , 1991, Annals of internal medicine.

[13]  D. Dunn,et al.  Pancreaticoduodenal transplantation with enteric drainage following native total pancreatectomy for chronic pancreatitis: a case report. , 1991, Pancreas.

[14]  D. Pyke A critique of pancreas transplantation. , 1990, Clinical transplantation.

[15]  R. Loewenson,et al.  Influence of Pancreas Transplantation on Cardiorespiratory Reflexes, Nerve Conduction, and Mortality in Diabetes Mellitus , 1990, Diabetes.

[16]  J. Najarian,et al.  Effects of pancreatic transplantation on diabetic neuropathy. , 1990, The New England journal of medicine.

[17]  R. Bilous,et al.  The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes. , 1989, The New England journal of medicine.

[18]  R. Ramsay,et al.  Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus. , 1988, The New England journal of medicine.

[19]  R. Ramsay,et al.  Pancreas transplantation in nonuremic, type I diabetic recipients. , 1988, Surgery.

[20]  G. Ghirlanda,et al.  Insulin, C-peptide, glucagon, and somatostatin secretion in segmental pancreatic autotransplantation. , 1984, Transplantation proceedings.